Dr. Scott Gottlieb on J&J vaccine trial results, Covid mutations and more

Dr. Scott Gottlieb on J&J vaccine trial results, Covid mutations and moreПодробнее

Dr. Scott Gottlieb on Covid-19 vaccine distribution, case counts and new variantsПодробнее

For FDA chief Scott Gottlieb: J&J Covid vaccine should work against delta variantПодробнее

AstraZeneca is a leading contender: Dr. Scott Gottlieb on J&J, AstraZeneca to restart vaccine trialsПодробнее

Dr. Scott Gottlieb: Don't 'overinterpret' decision to pause J&J vaccine over rare clotting issueПодробнее

Dr. Gottlieb on key J&J vaccine meeting, reports of new Covid variantПодробнее

How J&J's Covid-19 vaccine efficacy compares to the other candidatesПодробнее

Study on coronavirus mutation doesn't prove new strain is more infectious: Dr. Scott GottliebПодробнее

Dr. Scott Gottlieb discusses effectiveness of J&J Covid-19 vaccineПодробнее

Former FDA chief Scott Gottlieb on J&J's application for emergency use authorizationПодробнее

Dr. Scott Gottlieb: The vaccines might be sufficient to control spread of new Covid variantПодробнее

Dr. Scott Gottlieb on future of COVID-19, vaccine, and Pfizer | USA TODAYПодробнее

Dr. Scott Gottlieb discusses the rise in variant Covid casesПодробнее

Millions of coronavirus vaccine doses could be ready in the fall for human trials: Dr. GottliebПодробнее

Pfizer board member Scott Gottlieb on variant-specific Covid vaccineПодробнее

Pfizer board member Dr. Scott Gottlieb details likelihood of coronavirus vaccine in late NovemberПодробнее

Dr. Scott Gottlieb on the timeline for children's Covid vaccineПодробнее

Pfizer board member Scott Gottlieb on promising preliminary vaccine resultsПодробнее

Pfizer board member Dr. Scott Gottlieb on company's vaccine timelineПодробнее

Dr. Scott Gottlieb explains the potential of Gilead's coronavirus treatmentПодробнее